A prospective evaluation of pancreatic cyst surveillance, based on the consensus statement, formulated by the European study group on cystic tumours of the pancreas

A prospective evaluation of pancreatic cyst surveillance, based on the consensus statement, formulated by the European study group on cystic tumours of the pancreas - Pancreatic cyst follow-up an international collaboration/ PACYFIC study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55977

Enrollment

2500

Registered

2013-12-19

Start date

2015-06-24

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cyst, cystic tumor of the pancreas Pancreatic cyst

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Individuals with a pancreatic cyst (either newly or previously diagnosed) • Cyst surveillance is warranted, according to the treating physician • Age >18 • Informed consent

Exclusion criteria

Exclusion criteria: • History of chronic pancreatitis • Suspected pseudocyst • Suspected serous cystadenoma • Von Hippel-Lindau disease • Limited life expectancy (

Design outcomes

Primary

Measure	Time frame
Primary endpoints are: 1. Number of cysts reaching an indication for resection. 2. Number of patients, diagnosed with a malignant cyst (either high-grade dysplasia or carcinoma).	—

Secondary

Measure	Time frame
Secondary endpoints are to evaluate: 1. The course of patients with an indication for cyst resection (surgery, outcome, and recurrence). 2. Cyst evolution, in terms of development of symptoms, cyst growth, nodules, and secondary duct dilation. 3. The perceived burden of surveillance for participating subjects. 4. Potential risk factors for malignancy. and 5. To build a micro-simulation screening analysis (MISCAN) model, based on the outcome data of this study, in order to determine the optimal surveillance strategy for pancreatic cysts.	—

Measure

Time frame

Secondary endpoints are to evaluate: 1. The course of patients with an indication for cyst resection (surgery, outcome, and recurrence). 2. Cyst evolution, in terms of development of symptoms, cyst growth, nodules, and secondary duct dilation. 3. The perceived burden of surveillance for participating subjects. 4. Potential risk factors for malignancy. and 5. To build a micro-simulation screening analysis (MISCAN) model, based on the outcome data of this study, in order to determine the optimal surveillance strategy for pancreatic cysts.

—

Countries

Belgium, Canada, Finland, Germany, Hungary, Italy, Lithuania, Malta, Netherlands, Poland, Serbia, Spain, Sweden, United States

Contacts

Public ContactMBW Nix

Erasmus MC, Universitair Medisch Centrum Rotterdam

pacyfic@erasmusmc.nl+31 10 703 9230

Outcome results